Skip to content
Back to meeting Original
UT MD Anderson· @UTMDAnderson · X·· 1 day agoScore70
Body

Dr. Ferdinandos Skoulidis of UT MD Anderson presents late-breaking results from the Phase 3 KRAScendo 1 trial in the Presidential Symposium at #ESMO26. The findings offer new insights into targeted treatment for patients with previously treated advanced lung cancer with a KRAS G12C mutation.

Learn more: http://spr.ly/6018BH5yCi @FSkoulidis #EndCancer

182 views · 1 like · 0 reposts · 0 replies

Conference abstracts

Source: UT MD Anderson · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.